Clinical significance of high expression of proliferating cell nuclear antigen in non-small cell lung cancer

Abstract

Although proliferating cell nuclear antigen (PCNA) plays an important role in tumor proliferation and its expression level is closely related to the biological activity of tumor cells, PCNA expression in non-small cell lung cancer (NSCLC) has been seldom reported. In this study, we aimed to investigate the significance of PCNA expression in NSCLC tissues. PCNA expression in NSCLC and adjacent tissues were assessed by immunohistochemistry (IHC), western blotting, and reverse transcription polymerase chain reaction. Single factor analysis was used to study the relationship between the expression of PCNA and clinicopathological features of NSCLC. Multi-factor Cox survival analysis was used to evaluate the relationship between the expression of PCNA and overall survival of postoperative NSCLC patients. The areas under the receiver operating characteristics were calculated to evaluate the value of PCNA expression level in predicting the 3-year survival of NSCLC patients. IHC analysis showed that the positive expression rates of PCNA protein in NSCLC and adjacent tissues were 91.79% (257/280) and 25.83% (31/120), respectively. Western blotting confirmed that PCNA protein level was significantly higher in NSCLC tissues than in the adjacent tissues (P < .05). Reverse transcription polymerase chain reaction showed that the positive rate of PCNA mRNA in NSCLC was 88.93% (249/280), which was significantly higher than that in adjacent tissues 29.17% (35/120) (P < .05). Both PCNA mRNA and protein levels were correlated with tumor differentiation, size, metastasis, and stage in NSCLC. Patients exhibiting higher PCNA protein expression had a significantly shorter disease-specific survival rate than the other patients. PCNA protein level and tumor pathological type, metastasis, differentiation degree, and stage were independent factors affecting the overall survival of postoperative patients. The areas under the receiver operating characteristics of PCNA mRNA for predicting the 3-year survival of NSCLC patients was 0.89 (0.79–0.98), with a sensitivity and specificity of 0.84 and 0.76, respectively. In conclusion, high PCNA protein and mRNA levels may be associated with the occurrence, development, and prognosis of NSCLC.

Super enhancer‐LncRNA SENCR promoted cisplatin resistance and growth of NSCLC through upregulating FLI1

“…In addition, WB assay shown that knockdown of SENCR significantly reduced the expression of proliferation‐related protein PCNA, 20 cisplatin resistance‐related proteins MDMX 21 and P‐gp 22 in NSCLC cells (Figure 2I ), while overexpression of SENCR was reversed (Figure 2J ). These results suggested that SENCR promote proliferation and cisplatin resistance in NSCLC cells.…”

miR-1307 promotes hepatocarcinogenesis by CALR-OSTC-endoplasmic reticulum protein folding pathway

“…PCNA has been reported to be highly expressed in many cancers, such as non-small-cell lung cancer, breast cancer, etc. ( Ye et al., 2020 ). It is suggested that miR-1307 changes the expression of cyclin-related proteins pRB, PCNA, p21waf1/cip1, GADD45, P18, and ppRB dependent on CALR-OSTC-endoplasmic reticulum protein folding pathway.…”

The Implication of Autoantibodies in Early Diagnosis and Monitoring of Plasmonic Photothermal Therapy in the Treatment of Feline Mammary Carcinoma

“…While the fourth TAAs (PCNA), it is the rst time to study the relationship between its AAbs and mammary tumors concerning that PCNA TAAs were detected in sera of diseased animals with various types of cancers such as duodenal, breast and in non-small lung cancers and considered as an important prognostic indicator of cancer. Authors added that PCNA TAA high levels of expression were closely related to the occurrence, development, and prognosis of BC [43]. Although the detection of the autoantibodies accepted a raise of interest as a tool for diagnosis, early diagnosis, and monitoring of treatment response of different therapeutic modalities in cancers including breast cancer, PCNA autoantibodies have been seldom reported.…”